McKesson Europe

EQS-News: Federal Court of Justice (BGH) confirms additional payments for former shareholders of STADA Arzneimittel AG

Retrieved on: 
Thursday, February 8, 2024
Federal, SDK, BGH, Telephone, German, Federal Gazette, McKesson Europe, Bidding, Bain Capital, Stada Arzneimittel, News, Sale, EUR, Federal court, Security (finance)

Within the acceptance period (until the end of August 16, 2017), the bidder's offer was accepted by 63.76 % of STADA shareholders and within a further acceptance period (until September 1, 2017) by a further 0.11 % of STADA shareholders.

Key Points: 
  • Within the acceptance period (until the end of August 16, 2017), the bidder's offer was accepted by 63.76 % of STADA shareholders and within a further acceptance period (until September 1, 2017) by a further 0.11 % of STADA shareholders.
  • The bidder thus achieved a tender volume, including shares held by STADA, of approx.
  • In the opinion of the Bidder, the statute of limitations generally began at the latest at the end of 2017.
  • Former shareholders can register free of charge and without obligation at www.sdk.org/stada and will then receive all information on the proceedings.

Ondine Biomedical appoints new Board of Directors

Retrieved on: 
Tuesday, December 7, 2021
MSD, Merck, Solution, Public policy, Supervisory board, GLOBE, Medical Affairs Bureau, House, Audit committee, COO, CureVac, Reckitt, Board of directors, Eyeish, McCarthy, IPO, CEO, Medtech, RCGP, Therapy, ABPI, Partnership, McKesson Europe, EMEA, Board, Canadian House of Commons Page Program, Subclinical infection, Merck Sharp & Dohme Federal Credit Union, Microsoft Research, Entrepreneurship, NHS, NHS Confederation, Health Foundation, Pharmacia, The Advisory Board Company, Senior, Telefónica, Upjohn, Elanco, Partner, Legacy Fighting Alliance in 2018, CIPFA, Nose, Doctor of Philosophy, Merck & Co., Hospital, Silence Therapeutics, Acquisition, CFO, Commons, Management, Pharmaceutical industry

Vancouver, Canada, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Canadian life sciences company, Ondine Biomedical, has appointed a new Board of Directors with considerable medtech and pharma expertise following its listing on the London AIM market.

Key Points: 
  • Vancouver, Canada, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Canadian life sciences company, Ondine Biomedical, has appointed a new Board of Directors with considerable medtech and pharma expertise following its listing on the London AIM market.
  • Carolyn Cross, Founder and CEO of Ondine, and Nicolas G. Loebel, PhD, President and Chief Technology Officer, will remain on the Board.
  • Ondine is at the forefront of development of photodisinfection-based therapies to address the large and growing need for solutions to a broad spectrum infections, including drug-resistant strains.
  • Steriwave has been deployed in Canadian hospitals for over ten years and has contributed to significant reductions in infection rates.

VIRALEZE™ antiviral nasal spray launched in ADMENTA Italia Group pharmacies in Italy

Retrieved on: 
Friday, October 8, 2021
McKesson Corporation, Pharmacy, McKesson Europe, Marketing, Virus, LloydsPharmacy, Hospital, Severe acute respiratory syndrome coronavirus 2, CEO, Nose, Grocery store

MELBOURNE, Australia, Oct. 8, 2021 /PRNewswire/ --Australian biotech company Starpharma today announced it has signed a sales and distribution agreement for its VIRALEZE antiviral nasal spray with ADMENTA Italia Group (ADMENTA), a leading pharmaceutical retail and wholesale distribution company in Italy.

Key Points: 
  • MELBOURNE, Australia, Oct. 8, 2021 /PRNewswire/ --Australian biotech company Starpharma today announced it has signed a sales and distribution agreement for its VIRALEZE antiviral nasal spray with ADMENTA Italia Group (ADMENTA), a leading pharmaceutical retail and wholesale distribution company in Italy.
  • VIRALEZE is a broad-spectrum antiviral nasal spray, applied in the nose to provide a physical barrier between viruses and the nasal mucous membrane which traps and irreversibly inactivates viruses, including SARS-CoV-2.
  • ADMENTA employs 1,400 people in Italy across its wholesale and retail operations, supplying more than 2,500 pharmacies, parapharmacies, drug stores and hospitals.
  • Vincenzo Masci, Marketing and Procurement Director of ADMENTA-LloydsFarmacia, said: "We are delighted to have partnered with Starpharma for VIRALEZE antiviral nasal spray in Italy.

McKesson Raises Quarterly Dividend by 12% to $0.47 Per Share

Retrieved on: 
Monday, July 26, 2021
Public policy, Government, Pharmaceutical, General Health, Health, Medical devices, Healthcare reform, Supply chain management, Retail, McKesson Corporation, Pharmacy, MCK, Healthcare industry, Companies, Economy of the United States, Health care, McKesson Europe, Specialty drugs in the United States

The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 23, 2021 a regular dividend of $0.47 per share of common stock, a 12% increase from $0.42 per share in the prior quarter.

Key Points: 
  • The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 23, 2021 a regular dividend of $0.47 per share of common stock, a 12% increase from $0.42 per share in the prior quarter.
  • The dividend will be payable on October 1, 2021, to stockholders of record on September 1, 2021.
  • McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions.
  • McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively.

McKesson Declares Quarterly Dividend

Retrieved on: 
Thursday, January 28, 2021
Supply chain management, Health, Retail, Pharmaceutical, Medical Supplies, McKesson Corporation, Health sciences, Pharmacy, MCK, Healthcare industry, Pharmaceutical sciences, Health care, McKesson Europe

The Board of Directors of McKesson Corporation (NYSE: MCK) yesterday declared a regular dividend of 42 cents per share of common stock.

Key Points: 
  • The Board of Directors of McKesson Corporation (NYSE: MCK) yesterday declared a regular dividend of 42 cents per share of common stock.
  • The dividend will be payable on April 1, 2021, to stockholders of record on March 2, 2021.
  • McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions.
  • McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively.

Michelle Snyder, Digital Health Veteran, Joins McKesson Ventures

Retrieved on: 
Tuesday, December 1, 2020
Other Health, General Health, Professional services, Pharmaceutical, Oncology, Data management, Venture capital, Technology, Biotechnology, Finance, Other Technology, Health, McKesson Corporation, Economy of the United States, Companies, McKesson Europe, Health care, Proxim

McKesson Ventures , the venture capital arm of McKesson Corporation , announces the expansion of its leadership team, welcoming Michelle Snyder as its newest investment partner.

Key Points: 
  • McKesson Ventures , the venture capital arm of McKesson Corporation , announces the expansion of its leadership team, welcoming Michelle Snyder as its newest investment partner.
  • Prior to joining McKesson Ventures, Snyder served as chief marketing officer for Welltok, a consumer health activation company.
  • McKesson Ventures will continue to expand its leadership, presence and expertise in oncology care, consumer health, digital pharmacy, biopharma clinical and commercial services, data and analytics and value-based care.
  • McKesson Ventures is a strategic venture firm backed by McKesson Corporation focusing on early and growth stage health technology and healthcare services companies.

Walgreens Boots Alliance and McKesson Complete the Formation of German Wholesale Joint Venture

Retrieved on: 
Monday, November 2, 2020
Discount, Variety, Seniors, Supermarket, Specialty, Convenience store, General Health, Pharmaceutical, Consumer, Health, Retail, Companies, McKesson Europe, Pharmacy, Health care, Walgreens, McKesson Corporation, Ornella Barra, Alliance Healthcare, Boots, MCK, WBA, Guangzhou Pharmaceuticals, Walgreens Boots Alliance, McKesson

Walgreens Boots Alliance (Nasdaq: WBA) and McKesson Corporation (NYSE: MCK) today announced the completion of their previously announced agreement to create a joint venture combining their respective pharmaceutical wholesale businesses in Germany, Alliance Healthcare Deutschland (AHD) and GEHE Pharma Handel (GEHE).

Key Points: 
  • Walgreens Boots Alliance (Nasdaq: WBA) and McKesson Corporation (NYSE: MCK) today announced the completion of their previously announced agreement to create a joint venture combining their respective pharmaceutical wholesale businesses in Germany, Alliance Healthcare Deutschland (AHD) and GEHE Pharma Handel (GEHE).
  • WBA holds a 70 percent controlling equity interest in the joint venture and McKesson holds the remaining 30 percent interest.
  • At Walgreens Boots Alliance, we all look forward to working together with McKesson Corporation on this joint venture, said Ornella Barra, co-chief operating officer, Walgreens Boots Alliance.
  • The completion of this strategic partnership with Walgreens Boots Alliance enables us to strengthen and secure the future of pharmaceutical distribution in the German market, said Kevin Kettler, chairman of the management board and president McKesson International.

McKesson Declares Quarterly Dividend

Retrieved on: 
Thursday, October 29, 2020
Supply chain management, Medical Supplies, Retail, Health, Other Health, Pharmaceutical, McKesson Corporation, Health sciences, Pharmacy, MCK, Healthcare industry, Pharmaceutical sciences, Health care, McKesson Europe

The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 42 cents per share of common stock.

Key Points: 
  • The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 42 cents per share of common stock.
  • The dividend will be payable on January 4, 2021, to stockholders of record on December 1, 2020.
  • McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions.
  • McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively.

McKesson Declares Quarterly Dividend July 29, 2020

Retrieved on: 
Wednesday, July 29, 2020
General Health, Pharmaceutical, Health, Medical Supplies, McKesson Corporation, Health, Pharmacy, MCK, Dividend, Pharmaceutical industry, McKesson Europe

The Board of Directors of McKesson Corporation (NYSE:MCK) today declared a regular dividend of 42 cents per share of common stock.

Key Points: 
  • The Board of Directors of McKesson Corporation (NYSE:MCK) today declared a regular dividend of 42 cents per share of common stock.
  • The dividend will be payable on October 1, 2020, to stockholders of record on September 1, 2020.
  • McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology.
  • McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively.